Literature DB >> 36191215

Escape from breast tumor dormancy: The convergence of obesity and menopause.

Roopali Roy1,2, Jiang Yang1,2, Takaya Shimura1,2, Lauren Merritt1, Justine Alluin1, Emily Man1, Cassandra Daisy1, Rama Aldakhlallah1, Deborah Dillon3, Susan Pories4,5, Lewis A Chodosh6, Marsha A Moses1,2.   

Abstract

Obesity is associated with an increased risk of, and a poor prognosis for, postmenopausal (PM) breast cancer (BC). Our goal was to determine whether diet-induced obesity (DIO) promotes 1) shorter tumor latency, 2) an escape from tumor dormancy, and 3) an acceleration of tumor growth and to elucidate the underlying mechanism(s). We have developed in vitro assays and PM breast tumor models complemented by a noninvasive imaging system to detect vascular invasion of dormant tumors and have used them to determine whether obesity promotes the escape from breast tumor dormancy and tumor growth by facilitating the switch to the vascular phenotype (SVP) in PM BC. Obese mice had significantly higher tumor frequency, higher tumor volume, and lower overall survival compared with lean mice. We demonstrate that DIO exacerbates mammary gland hyperplasia and neoplasia, reduces tumor latency, and increases tumor frequency via an earlier acquisition of the SVP. DIO establishes a local and systemic proangiogenic and inflammatory environment via the up-regulation of lipocalin-2 (LCN2), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) that may promote the escape from tumor dormancy and tumor progression. In addition, we show that targeting neovascularization via a multitargeted receptor tyrosine kinase inhibitor, sunitinib, can delay the acquisition of the SVP, thereby prolonging tumor latency, reducing tumor frequency, and increasing tumor-free survival, suggesting that targeting neovascularization may be a potential therapeutic strategy in obesity-associated PM BC progression. This study establishes the link between obesity and PM BC and, for the first time to our knowledge, bridges the dysfunctional neovascularization of obesity with the earliest stages of tumor development.

Entities:  

Keywords:  breast cancer; obesity; postmenopausal; tumor dormancy; vascular phenotype

Mesh:

Substances:

Year:  2022        PMID: 36191215      PMCID: PMC9564105          DOI: 10.1073/pnas.2204758119

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  69 in total

1.  Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans.

Authors:  Yu Wang; Karen S L Lam; Edward W Kraegen; Gary Sweeney; Jialiang Zhang; Annette W K Tso; Wing-Sun Chow; Nelson M S Wat; Jian Yu Xu; Ruby L C Hoo; Aimin Xu
Journal:  Clin Chem       Date:  2006-10-13       Impact factor: 8.327

2.  HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis.

Authors:  J Fang; L Yan; Y Shing; M A Moses
Journal:  Cancer Res       Date:  2001-08-01       Impact factor: 12.701

Review 3.  Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer.

Authors:  Y Li; W P Hively; H E Varmus
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

Review 4.  Targeting Cancer Cell Dormancy.

Authors:  Ariadna Recasens; Lenka Munoz
Journal:  Trends Pharmacol Sci       Date:  2019-01-03       Impact factor: 14.819

5.  Repression of vascular endothelial growth factor expression by the zinc finger transcription factor ZNF24.

Authors:  Jay Harper; Li Yan; Robyn M Loureiro; Iinmin Wu; Jianmin Fang; Patricia A D'Amore; Marsha A Moses
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

6.  Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.

Authors:  Joao Incio; Jennifer A Ligibel; Daniel T McManus; Priya Suboj; Keehoon Jung; Kosuke Kawaguchi; Matthias Pinter; Suboj Babykutty; Shan M Chin; Trupti D Vardam; Yuhui Huang; Nuh N Rahbari; Sylvie Roberge; Dannie Wang; Igor L Gomes-Santos; Stefan B Puchner; Christopher L Schlett; Udo Hoffmman; Marek Ancukiewicz; Sara M Tolaney; Ian E Krop; Dan G Duda; Yves Boucher; Dai Fukumura; Rakesh K Jain
Journal:  Sci Transl Med       Date:  2018-03-14       Impact factor: 17.956

7.  Adiponectin and breast cancer risk.

Authors:  Christos Mantzoros; Eleni Petridou; Nick Dessypris; Charilaos Chavelas; Maria Dalamaga; Delia Marina Alexe; Yannis Papadiamantis; Christos Markopoulos; Evangelos Spanos; George Chrousos; Dimitrios Trichopoulos
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

8.  Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.

Authors:  L Holmgren; M S O'Reilly; J Folkman
Journal:  Nat Med       Date:  1995-02       Impact factor: 53.440

Review 9.  Tumor dormancy of primary and secondary cancers.

Authors:  Taturo Udagawa
Journal:  APMIS       Date:  2008 Jul-Aug       Impact factor: 3.205

10.  Leptin regulation of the p53-HIF1α/PKM2-aromatase axis in breast adipose stromal cells: a novel mechanism for the obesity-breast cancer link.

Authors:  H Zahid; K Subbaramaiah; N M Iyengar; X K Zhou; I-C Chen; P Bhardwaj; A Gucalp; M Morrow; C A Hudis; A J Dannenberg; K A Brown
Journal:  Int J Obes (Lond)       Date:  2017-11-06       Impact factor: 5.095

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.